Company intelligence / Profile preview

Sinopharm Wuhan Biopharmaceuticals Co., Ltd.

Wuhan, Hubei Province, China

Ownership: Private
Development stage: Commercial

Overview

The company conducted a Phase 2 clinical trial for Human COVID-19 immunoglobulin (pH4) for intravenous injection (COVID-HIG) in the treatment of patients with COVID-19, which started on December 30, 2021. They also have Human prothrombin complex for Hemophilia B in IND approval stage.

Therapeutic areas: HematologyInfectious Diseases
Modalities: Blood productsPlasma-derived biotherapiesImmunoglobulins
Industry: Biotech

Drug pipeline

1 asset

Human COVID-19 immunoglobulin (pH4) for intravenous injection

Unknown

Beyond the preview

Go deeper on Sinopharm Wuhan Biopharmaceuticals Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sinopharm Wuhan Biopharmaceuticals Co., Ltd..

Explore the full profile